Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Status:
Completed
Trial end date:
2017-11-23
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent
asthma.
Secondary Objectives:
- To evaluate the safety and tolerability of dupilumab.
- To evaluate the effect of dupilumab on improving participant-reported outcomes including
health-related quality of life.
- To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.